Key Points
- Insider sale: BioLife Solutions director Karen Foster sold 519 shares on December 9 at an average price of $25.13 for $13,042, leaving her with 192,319 shares (a 0.27% reduction, valued at about $4.83M).
- Stock and valuation snapshot: BLFS traded up 2.7% to $25.69 with light volume (53,084 vs. avg 443,760), a market cap of $1.24B, a negative P/E (~-368), and a 52-week range of $19.10–$29.62.
- Institutional and analyst picture: Institutions own ~93.24% of the stock, and analysts have a "Moderate Buy" consensus with a $30.75 average target (4 Buys, 1 Hold, 1 Sell).
BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Karen Foster sold 519 shares of the business's stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $25.13, for a total value of $13,042.47. Following the transaction, the insider owned 192,319 shares of the company's stock, valued at $4,832,976.47. This represents a 0.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
BioLife Solutions Stock Up 2.7%
NASDAQ BLFS traded up $0.68 during trading hours on Thursday, hitting $25.69. The company had a trading volume of 53,084 shares, compared to its average volume of 443,760. The firm has a market cap of $1.24 billion, a P/E ratio of -368.03 and a beta of 1.93. BioLife Solutions, Inc. has a fifty-two week low of $19.10 and a fifty-two week high of $29.62. The business has a fifty day simple moving average of $26.34 and a 200-day simple moving average of $24.52.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wyoming increased its stake in shares of BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 1,490 shares during the period. Hantz Financial Services Inc. boosted its stake in BioLife Solutions by 54.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider's stock valued at $48,000 after purchasing an additional 659 shares in the last quarter. US Bancorp DE increased its position in shares of BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after purchasing an additional 1,528 shares during the period. Quarry LP raised its stake in shares of BioLife Solutions by 50.9% in the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider's stock worth $54,000 after buying an additional 713 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock valued at $83,000 after buying an additional 441 shares during the period. 93.24% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on BLFS. HC Wainwright reiterated a "buy" rating and issued a $32.00 price objective on shares of BioLife Solutions in a research report on Monday, November 24th. Zacks Research cut BioLife Solutions from a "strong-buy" rating to a "hold" rating in a report on Monday, December 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut BioLife Solutions from a "buy" rating to a "hold" rating in a research report on Sunday, November 30th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $30.75.
Read Our Latest Stock Report on BLFS
BioLife Solutions Company Profile
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
